<DOC>
	<DOCNO>NCT02197975</DOCNO>
	<brief_summary>Safety Pharmacokinetics Two Doses PT010 Healthy Adult Subjects Japanese Descent Following Single Dose After Chronic Dosing 7 Days .</brief_summary>
	<brief_title>Randomized , Crossover Safety Pharmacokinetics Study PT010</brief_title>
	<detailed_description>This Phase I , single-center , randomize , double-blind , placebo-controlled , two period , ascend dose , cross-over study assess safety PK two dos PT010 healthy adult subject Japanese descent . Safety PK assess follow single dose twice-daily ( BID ) chronic dose 7 day .</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Informed Consent Form ( ICF ) prior study related procedure Male female subject first generation Japanese subject 18 55 year , inclusive Body weight â‰¥50 kg ( 110 lb ) Screening Visit body mass index 18.5 32 kg/m2 , inclusive Good general health Medically acceptable contraception woman childbearing potential male female partner childbearing potential Clinical lab within normal range determine clinically significant Investigator Pregnancy , nurse female subject , subject try conceive Clinically significant neurologic , cardiovascular , hepatic , renal , endocrinologic , pulmonary , hematological , psychiatric , medical illness would interfere participation study History ECG abnormalities Cancer complete remission least 5 year Clinically significant , symptomatic prostatic hypertrophy Male subject transurethral resection prostate full resection prostate within 6 month prior Screening Clinically significant bladder neck obstruction urinary retention Inadequately treat glaucoma History allergic reaction hypersensitivity drug component formulation use study Subjects preexist anemia and/or iron deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>